| From: Moonray | 4/12/2021 1:18:56 PM | | | | | | Lilly says U.S. government modified purchases
of its COVID-19 antibody treatments
By Jaimy Lee - April 12, 2021
Shares of Eli Lilly & Co. LLY, -1.14% were up 0.3% in premarket trading on Monday after the company said the U.S. government modified purchase agreements for its COVID-19 antibody therapies. The agreement for bamlanivimab, which was the first Lilly antibody treatment to receive emergency authorization, now includes etesevimab. Using a combination of the two antibody therapies is more effective against some of the new virus variants that have emerged. Lilly said the new agreement terminates the original purchase agreement for bamlanivimab and in effect cancels the roughly 350,000 doses of bamlanivimab that had been scheduled for delivery in March. Lilly's stock has gained 9.2% since the start of the year, while the S&P 500 SPX, -0.07% has gained 9.9%.
o~~~ O
|
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 5/4/2021 3:30:51 PM | | | | | | Lilly Announces Global Donations of COVID Treatments
By Wes Mills, May 4th 2021
INDIANAPOLIS - Indianapolis-based Eli Lilly and Co. (NYSE: LLY)
says it will donate an unspecified amount of its COVID-19 therapies
to low and lower-middle-income countries most heavily affected by
the pandemic. The company says it will donate both baricitinib as
well as its cocktail prescription of bamlanivimab and etesevimab,
which provides options to treat COVID-19 patients at different stages
of the disease.
The announcement comes as the company also says it will provide
400,000 doses of baricitinib to the Indian government for COVID-19
patients who are hospitalized.
The World Health Organization reported Tuesday that India recorded
nearly 360,000 new cases of the disease over the past 24 hours
Lilly Chairman and Chief Executive Officer David Ricks says even
as the world makes progress on vaccine rollouts, it remains vital for
treatments to be made available.
“Bamlanivimab with etesevimab together reduces the risk of hos-
pitalizations and death for high-risk patients in the outpatient setting,
while recent data show baricitinib in addition to current standard of
care reduces death in hospitalized patients,” said Ricks.
Lilly says it will work with global humanitarian nonprofit Direct Relief
to allocate the treatments. The initiative will begin immediately.
The company says the allocation will be based on the disease burden
and hospitalization rates in each country.
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 6/1/2021 9:07:44 PM | | | | | | EXCLUSIVE U.S. opens criminal probe into alleged lapses at Eli Lilly plant
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (LLY.N)focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giant’s COVID-19 therapy and other drugs, three people familiar with the matter said.
The probe represents a significant escalation of the government scrutiny on Lilly. The pharmaceutical company, one of the world's largest, has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the Branchburg factory.
Reuters questioned Lilly about the criminal inquiry on Wednesday. On Thursday morning, the company disclosed in a securities filing that it had received a subpoena from the Justice Department in May seeking documents related to the Branchburg factory.
The company did not disclose anything more about the nature or focus of the investigation and said it was cooperating fully in the matter.
More at: reuters.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 6/1/2021 9:20:34 PM | | | | | | Eli Lilly gets Indian emergency use nod for Covid-19 antibody drug combination
The company said it is in talks with the Indian government and regulatory authorities to donate the drugs to help speed up access and provide more treatment options for Covid-19
Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate Covid-19, bolstering the country's arsenal of medicines to tackle a devastating second wave of the pandemic.
A combination of the U.S. drugmaker's monoclonal antibodies bamlanivimab and etesevimab has been given approval for restricted use in emergency situations in hospital settings in adults, the company's Indian unit said in an emailed statement.
More at: kathmandupost.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 6/1/2021 9:27:56 PM | | | | | | Distribution of Eli Lilly COVID-19 therapy
paused in 8 states over variant concerns
For now, the FDA recommends using
Regeneron's antibody cocktail instead.
Federal health authorities have paused distribution
of Eli Lilly's monoclonal antibody cocktail in eight
tates over COVID-19 variant efficacy concerns.
The COVID-19 treatment will halt distribution in
Arizona,
alifornia,
Florida,
llinois,
Indiana,
Massachusetts,
Oregon and
Washington
"until further notice" due to variants' elevation in those
states, the U.S. Department of Health and Human
Services and Assistant Secretary for Preparedness
and Response announced in a bulletin this week.
More at: abcnews.go.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
